Respules Global Market Report 2024

Respule, also recognized as respiratory medications, is a steroid utilized for the prevention of asthma attacks. It alleviates symptoms associated with asthma and chronic obstructive pulmonary disease (COPD), such as coughing, wheezing, and breathlessness.

The primary categories of respule drugs include budesonide, albuterol, ipratropium bromide, salbutamol sulfate, and ipratropium bromide. Budesonide is a synthetically produced glucocorticoid steroid known for its potent topical anti-inflammatory properties. Various dosage types and strengths, such as 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml, and others, are available and distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and more.

The respules market research report is one of a series of new reports from The Business Research Company that provides respules market statistics, including respules industry global market size, regional shares, competitors with a respules market share, detailed respules market segments, market trends and opportunities, and any further data you may need to thrive in the respules industry. This respules market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The respules market size has grown strongly in recent years. It will grow from $1.69 billion in 2023 to $1.83 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth observed in the historical period can be ascribed to factors such as recommendations from physicians, enhancements in healthcare access, advancements in clinical research and development, increased adoption of inhalation therapy, awareness campaigns, and growth in the pharmaceutical industry.

The respules market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The anticipated growth in the forecast period can be credited to progress in drug formulations, the advent of biologic therapies, the integration of smart inhalers and connectivity, the adoption of personalized medicine approaches, the rise of telemedicine and remote care, and regulatory backing for inhalation therapy. Noteworthy trends expected in the forecast period encompass sustainable manufacturing practices, the development of remote monitoring and compliance tools, the emergence of patient-centric inhalation solutions, the advancement of respiratory inhalation vaccines, and the introduction of customizable dosage respules.

The growth in the respules market is anticipated to be propelled by the increasing incidence of respiratory disorders. Respiratory disorders encompass various lung diseases such as tuberculosis, lung cancer, pulmonary hypertension, mesothelioma, cystic fibrosis, emphysema, and asthma. Respules serve as a treatment for a range of respiratory disorders, addressing conditions such as bronchial asthma, emphysema, spasmodic stenosis, and abnormal bronchial mucus production. As an illustration, data from the Australian Institute of Health and Welfare in June 2023 revealed that in 2021, there were approximately 6,551 deaths related to chronic respiratory conditions in Australia, accounting for 27.1% of all deaths. Moreover, chronic obstructive pulmonary disease (COPD) constituted 2.6% of underlying-cause respiratory deaths. Hence, the escalating incidence of respiratory disorders is a key driver for the respules market.

The surge in air pollution is also expected to contribute to the growth of the respules market. Air pollution, characterized by the presence of harmful substances and contaminants in the Earth's atmosphere, poses risks to human health, the environment, and the climate. Respules often contain bronchodilators or corticosteroids to alleviate symptoms such as wheezing and shortness of breath, which can be triggered by exposure to air pollution. For example, data from IQAir in September 2021 highlighted a 25% increase in PM2.5 concentrations in Malaysia compared to the previous year, and 11 out of the 15 most polluted cities in Central and South Asia were located in India. Delhi, specifically, experienced a 14.6% surge in PM2.5 concentrations, surpassing WHO air quality guidelines. The rise in air pollution levels is thus contributing to the growth of the respules market.

Major players in the respules market are introducing novel products, such as inhalation suspensions, to secure a competitive advantage. Inhalation suspensions are pharmaceutical formulations characterized by finely dispersed solid or liquid particles suspended in a liquid medium. A notable example is The Ritedose Corporation, a US-based pharmaceutical company, which unveiled a new single unit dose generic product for hospitals in December 2021, Budesonide Inhalation Suspension (0.5 mg/2 ml). This product, featuring 30 single-dose ampules per carton, individually wrapped and barcoded, provides hospitals with a dependable and substantial supply. Budesonide inhalation suspension typically incorporates the corticosteroid budesonide, serving as an anti-inflammatory agent for managing respiratory conditions by mitigating inflammation and associated symptoms in diseases such as asthma.

Leading companies in the respules market are also engaging in strategic partnerships to fortify their market positions and introduce innovative products. Collaborations and partnerships in this market facilitate broader market reach, expanded distribution networks, and heightened research and development initiatives, thereby contributing to the success and growth of respiratory medication products. For instance, in July 2023, Viatris Inc., a US-based pharmaceutical company, collaborated with Kindeva Drug Delivery L.P., a US-based pharmaceutical contract development and manufacturing organization (CDMO), to jointly launch Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. As the first FDA-approved generic version of AstraZeneca's Symbicort for asthma and chronic obstructive pulmonary disease (COPD), Breyna offers accessible and cost-effective treatment options for individuals facing respiratory challenges. Available in 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths, Breyna addresses the maintenance treatment of airflow obstruction, reduces exacerbations in COPD patients, and manages asthma symptoms in patients six years and older.

In February 2022, Glenmark Pharmaceuticals, an India-based pharmaceutical company, collaborated with AstraZeneca, a UK-based pharmaceutical and biotechnology company, to commercialize Pulmicort Respules in Colombia. As part of this agreement, AstraZeneca retains the production and registration ownership of Pulmicort Respules, ensuring continued and expanded access to this essential treatment for people living with asthma in Colombia.

Major companies operating in the respules market report are AstraZeneca PLC, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Limited, Intas Pharmaceuticals Ltd., Lupin Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ranbaxy Laboratories Limited, Systopic Laboratories Pvt. Ltd., Ultratech India Limited, Koye Pharmaceuticals Pvt. Ltd., Amanta Healthcare Ltd., Lucky Pharmaceuticals, Medicamen Biotech Limited, Axa Parenterals Ltd., Zuche Pharmaceuticals Pvt. Ltd., Jaksh Pharma, Biochemix Healthcare Private Limited, Intra Life Pvt. Ltd., Wellona Pharmaceuticals Private Limited, Percept Pharma Limited, Eurocrit Labs, Iskon Remedies

North America was the largest region in the respules market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respules market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the respules market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The respule market consists of sales of budesonide, disodium edetate, sodium chloride, citric acid, and sterile solution. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Respules Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on respules market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for respules ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The respules market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Type: Budesonide; Albuterol; Ipratropium Bromide; Salbutamol Sulphate And Ipratropium Bromide
• 2) By Dosage And Strength: 0.25 mg/2 mL; 0.5 mg/2 mL; 1mg/2 mL; Other Dosage And Strength Types
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• Companies Mentioned: AstraZeneca PLC; GlaxoSmithKline PLC; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Sandoz International GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.